Genetic association of monocyte chemoattractant protein 1 (MCP-1)-2518 polymorphism in Mexican patients with transitional cell carcinoma of the bladder

Urology. 2009 Aug;74(2):414-8. doi: 10.1016/j.urology.2009.04.016.

Abstract

Objective: To investigate the role of MCP-1-2518, stromal cell-derived factor-1 (SDF-1)-G801A and chemokine receptors CCR5-Delta32, CCR5-59 029, and CCR2-64I gene polymorphisms in transitional cell carcinoma of the bladder in Mexican Mestizo patients.

Methods: Forty-seven unrelated consecutive patients with non-muscle-invasive transitional cell carcinoma (TCC) and 126 unrelated healthy individuals were studied. Genomic extraction was carried out from complete blood samples using the salting out method. The PCR-RFLP method was used to amplify the following polymorphisms: MCP-1-2518, SDF-1-G801A, CCR5-Delta32, CCR5-59 029, and CCR2-64I.

Results: The patients were divided according to low, intermediate, and high risk of progression and treated accordingly with surveillance or immunotherapy with BCG. SDF-1-G801A, CCR5-Delta32, CCR5-59 029, and CCR2-64I polymorphisms were not associated with the genetic susceptibility to non-muscle-invasive TCC of the bladder in Mexican patients. The distribution of AA, AG, and GG genotypes of MCP-1-2518 was significantly different in bladder cancer patients compared with controls (P = .006). There was a significant decrease both in the frequency of the G mutant allele (P = .021, OR = 1.752; C 95% CI 1.088-2.828) and in the GG genotype (P = .001, OR = 6.097 95% CI 1.885-19.570) in TCC patients, compared with controls.

Conclusions: This preliminary study shows that MCP-1 polymorphism is associated with TCC.

MeSH terms

  • Adult
  • Aged
  • Alleles
  • BCG Vaccine / therapeutic use
  • Carcinoma, Transitional Cell / drug therapy
  • Carcinoma, Transitional Cell / genetics*
  • Chemokine CCL2 / genetics*
  • Chemokine CXCL12 / genetics
  • Female
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Male
  • Middle Aged
  • Polymorphism, Genetic*
  • Receptors, CCR2 / genetics
  • Receptors, CCR5 / genetics
  • Receptors, Chemokine / genetics*
  • Reverse Transcriptase Polymerase Chain Reaction
  • Urinary Bladder Neoplasms / drug therapy
  • Urinary Bladder Neoplasms / genetics*
  • Young Adult

Substances

  • BCG Vaccine
  • Chemokine CCL2
  • Chemokine CXCL12
  • Receptors, CCR2
  • Receptors, CCR5
  • Receptors, Chemokine